Surgery Medical News about breast cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Axillary-conserving surgery is facilitated by neoadjuvant chemotherapy of breast cancer
The American Journal of Surgery, 05/13/09

Beatty AD et al. - In a trial to examine the downstaging of breast cancer axillary lymph node (ALN) metastasis by neoadjuvant chemotherapy (NCT) and potential facilitation of axillary-conserving surgery, it was shown that NCT downstages primary breast cancer and ALN metastasis. ALN and SLN biopsy following, rather than before, NCT facilitate both breast- and axillary-conserving surgery.

Methods

Records of breast cancer pts treated with NCT, breast surgery, and pathological ALN assessment were reviewed using the institutional breast cancer database.

Results

Of 473 cases, 309 (65%) were clinically ALN-positive (cN+) and 164 (35%) were clinically ALN-negative (cN-).
Pre-NCT, needle biopsy, sentinel lymph node (SLN) biopsy, or axillary dissection documented metastasis in 94% (117/124) of cN+ and 27% (13/49) of cN- pts tested.
Pathological complete response of ALNs to NCT was documented in 36% (41/115) of pts.
False negative SLN biopsy following NCT occurred in 4% of cases (1/28).

<< Previous
Phase II study of regional treatment for peritoneal...

Next >>
Operative innovation to the “Nuss” procedure for pectus...